Patricia J. Emmanuel, MD, FAAP

Patricia J. Emmanuel, M.D., received her Medical Degree from the University of Florida. She performed her Pediatric Internship and Residency at the University of South Florida in Tampa, where she was Chief Resident. She completed a fellowship in Pediatric and Adult Infectious Diseases at the same institution. She is board certified in Pediatrics and Pediatric Infectious Disease. Dr Emmanuel is currently a Professor of Pediatrics and Division Chief of Infectious Disease at the University of South Florida, College of Medicine.

Dr. Emmanuel has been Medical Director for the University of South Florida HIV Program for children and adolescents since 1995. The USF Program provides primary and specialty care to children and adolescents in Southwest Florida. Dr Emmanuel is principle investigator for the USF Adolescent Trials Network, the Title IV Youth Initiative and the International Maternal Pediatric Adolescent AIDS Clinical Trials Group. Research interests include antiretroviral drug treatment for HIV, community perinatal HIV prevention methods and long-term complications of HIV. She has participated in NIH and industry-sponsored HIV clinical drug trials. Dr. Emmanuel participates in HIV policy making at the national level as a member of the Committee on Pediatric AIDS for the AAP and the HIV Medicine Association.

Selected Publications

Luque MA, Cavallaro DL, Torres M, Emmanuel PJ, Hillman, JV: Pneumomediastinum, pneumothorax, and subcutaneous emphysema after alternate cocaine inhalation and marijuana smoking. Pediatric Emergency Care, 3: 107, 1987.

Sinnott JT, Rodnite J, Emmanuel PJ, Campos A, Cryptococcus laurentii infection complicating peritoneal dialysis. The Pediatric Infectious Disease Journal, 8: 803-805, 1989.

Sinnott JT, Emmanuel PJ, Mycobacterial Infections in the Transplant Patient. Seminars in Respiratory Infections, 5:65-73, 1990.

Chan GL, Sinnott JT, Emmanuel PJ, Yandle S, Weinstein S, Drug Interactions with Cyclosporine: Focus on Antimicrobial Agents.Clinical Transplantation, 6:141, 1992.

Gieron-Korthals MA, Westberry KR, Emmanuel PJ; Acute Childhood Ataxia: 10Year Experience. J Child Neurology, 9:381-384,1994.

James-Yarish M, Bradley WG, Emmanuel PJ, Good RA, Day NB; Detection of cell specific cluster determinant expression by reverse transcriptase polymerase chain reaction. Journal of Immunological Methods, 169: 73-82,1994.

Ackerman J, Emmanuel PJ, Gilbert-Barness E; Pathological Case of the Month; Hepatosplenic Cat Scratch Disease. Arch. Pediatric Adolescent Medicine. 149: 821-822,1995.

Sarazier JS, Green JN, Sandin RL, Spiers ASD, Emmanuel PJ, Valder RF, Gombert ME, and Vincent AL; Disseminated Nocardia Brasiliensis Infection in an Immunocompromised Patient. Cancer Control, 5(1): 64,1998.

Haraguchi S, Day NK, Nelson, RP, Emmanuel PJ, Duplantier, JE, Christodoulou C, and Good R; Interleukin 12 deficiency associated with recurrent infections. Proc. Natl. Acad.Sci. 95:13125-13129, 1998.

Christodoulou CS, Emmanuel PJ, Ray R, Good R, Schnapf B, Cawkwell G; Respiratory Distress Due to Minocycline-Induced Pulmonary Lupus. CHEST, 115:1471-1473,1999.

Saez-Llorens X, Nelson R, Emmanuel PJ, Wiznia A, Church J, Sleasman J, VanDyke R, Richardson CG, Rosko C, Cutrell A, and Hetherington SV; A Randomized, Double-Blind Study of Triple Nucleoside Therapy Abacavir, Lamivudine and Zidovidine versus Lamivudine and Zidovidine in Previously Treated HIV-1 Infected Children. Pediatrics. Jan;107(1):E4, 2001.

Elfenbein D, Emmanuel PJ, Radiological Case of the Month-CNS Vasculitis in an HIV –infected Child. Arch Ped & Adol Med 155:849-850, 2001.

Tan BM, Nelson RP, James-Yarish M, Emmanuel PJ, Schurman SJ. Bone metabolism in HIV-infected Children receiving therapy including a protease inhibitor. J. of Pediatrics 139:447-51, 2001.

Brown C, Tangsinmankong N, Emmanuel PJ, "Improving Care of HIV-Infected Patients in the Outpatient Setting With Patient Data Flow Sheet". Journal of the Association of Nurses in AIDS Care. Vol. 13, No. 4, July/August 2002, 58-63.

Wang LH, Wisnia AA, Rathore MH, Chittick GE, Bakshi SS, Emmanuel PJ, Flynn PM. Pharmacokenetics and safety of single oral doses of emtricitabine in human immunodeficiency virus-infected children. Antimicrob Agents Chemother. 48 (1): 183-91, Jan 2004.

Maheshwari A, Stromquist CI, Pereda L, Emmanuel PJ. Mixed infection with unusual fungi and Staphylococcal species in to extremely premature neonates. Journal of Perinatology. 24 (5) 324-6, May 2004.

Tangsinmankong N, Kamchaisatian W, Day NK, Sleasman JW, Emmanuel P. Immunogenicity of 23-valent pneumococcal polysaccharide vaccine in HIV-1-infected children on highly active antiretroviral therapy (HAART). Ann Allergy Immunol. 92(5) 558-64, May 2004.

Tangsinmankong N, Kamchaisatian W, Lujan-Zilbermann J, Brown CL, Sleasman JW, Emmanuel PJ. Varicella Zoster as a Common Manifestation of Immune Restoration Disease in HIV Infected Children". J Allergy Clin Immunol 113 (4) 742-6, Apr 2004.

Emmanuel PJ, Chamyan G, Fisher JE, Gilbert-Barness E, Pomerance HH. Clinico-Pathologic Conference; 17-day-old girl with hypothermia, decreased feedings, liver and kidney failure. Fetal Pediatric Pathology. 23(1) 39-50 Jan 2004.

Rucker RP, Day NK, Good RA, Kamchaisatian W, Emmanuel P, Sleasman JW, Mayeski C, Dinglasan E, Haraguchi S, Tangsinmankong N. Influenza Virus Vaccine Decreases Expression of HIV Co receptor CCR5. Ann Allergy, Asthma and Immun. 93(3):272-6 Sept 2004.

Johnson S, Marion A, Vrhochticky T, Emmanuel P, Lujan-Zilbermann J. Cushing Syndrome with Secondary Adrenal Insufficiency from Concomitant Therapy with Ritonavir and Fluticasome. J Pediatr. 148:386-8, April 2006.

Lujan-Zilberman J, Rodriquez C, Emmanuel P. Laboratory Diagnosis of HIV Infection, Part I. Accepted for publication, Fetal Pediatric Pathology, August 2006.

Rodriquez C, Lujan-Zilberman J, Emmanuel P. Laboratory Methods to Manage HIV Infection, Part II. Accepted for publication, Fetal Pediatric Pathology, August 2006.

Wiznia A, Church J, Emmanuel P, Eppes S. Rowell L, Evans C, Bertasso A and the T20-310 Study Group. Safety and Efficacy of Enfuviritide for 48 weeks as part of an Optimized Antiretroviral Regimen in Pediatric Human Immunodeficiency Virus 1-Infected Patients. In preparation. July 2006.